This review aims to provide a comprehensive overview of the current literature on the drug
design, development, and therapy of lurasidone for the treatment of schizophrenia …

Objective This study aims to analysis adverse drug events (ADE) related to Brexpiprazole
from the third quarter of 2015 to the first quarter of 2023 from FAERS database. Methods The …

Objective Quetiapine, an atypical second‐generation antipsychotic drug, is approved for
treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of …

Aims Neratinib has emerged as significant theraputic option for breast cancer treatment.
However, despite its approval, numerous adverse drug events (ADEs) associated to it …

Background Clomiphene is widely used for the treatment of anovulatory infertility, yet there
remain many unrecognized adverse events (AEs). The objective of this study is to provide a …

Abstract Background The relationship between Protein Convertase Subtilisin Kexin Type 9
inhibitor (PCSK9i) and psychiatric adverse events (AEs) remains unclear due to the …

Background Dapagliflozin possesses the capacity to cure a wide range of diseases,
however, there are many adverse events (AEs) that have not yet been acknowledged or …

Background Tafamidis emerged as the first FDA-approved drug for treating termed amyloid
fibrils. This study aims to analyze adverse events (AEs) related to tafamidis from the second …

Abstract Background Cetirizine and Loratadine are the two best‐selling second‐generation
antihistamines for allergic diseases. This study aims to provide a comparative analysis of the …

Background The primary objective of this research is to conduct an exhaustive evaluation of
rimegepant with the Food and Drug Administration Adverse Event Reporting System …